IMI's test catches lung cancer early, study finds:
This article was originally published in Clinica
IMI International Medical Innovations has revealed that its LungAlert sputum test for lung cancer detected 20 of 23 cancers in a pilot study of the product. Most significantly, the test detected 13 of 15 early stage cancers, which are often still treatable, according to data from the 76-patient study, presented at last month's American Thoracic Society meeting in San Francisco. IMI, of Toronto, Canada, is investigating whether the noninvasive, quantitative test can provide a new screening tool for lung cancer (see Clinica No 946, p 18).